Blueprint Medicines (BPMC) Reports Q4 Net Loss of $5.40

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($5.40), $3.75 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $107.02 million versus the consensus estimate of $102.69 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Barclays says AI trade is maturing, favors greater diversification
• Investing.com’s stocks of the week